Company Filing History:
Years Active: 2021
Title: Chen Bai - Innovator in Antibody Engineering
Introduction
Chen Bai is a notable inventor based in Arlington, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of engineered antibodies. His work focuses on creating novel therapeutic agents that can effectively target and treat various proliferative disorders.
Latest Patents
Chen Bai holds a patent for "Conjugates of cysteine engineered antibodies." This invention relates to innovative cell-binding agent-cytotoxic agent conjugates. The cell-binding agent is covalently linked to the cytotoxic agent through an engineered cysteine, specifically in the heavy chain CH3 domain. This linkage occurs at a position corresponding to the EU/OU numbering position 442 (or C442) on an antibody cell-binding agent. The patent also outlines methods for preparing these conjugates and provides compositions and methods useful for inhibiting abnormal cell growth or treating proliferative disorders in mammals.
Career Highlights
Chen Bai is currently employed at Immunogen, Inc., a company known for its pioneering work in antibody-drug conjugates. His role involves extensive research and development aimed at advancing therapeutic options for cancer treatment. His innovative approach has positioned him as a key figure in the biotechnology sector.
Collaborations
Throughout his career, Chen Bai has collaborated with esteemed colleagues, including Nicholas C. Yoder and Michael Louis Miller. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking therapeutic solutions.
Conclusion
In summary, Chen Bai is a distinguished inventor whose work in antibody engineering has the potential to revolutionize treatments for proliferative disorders. His contributions to the field are marked by his innovative patent and collaborative efforts within the biotechnology community.